Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 13/20 | 0.57 |
| ▸ | JAK2 | O60674 | 11/20 | 0.57 |
| ▸ | JAK3 | P52333 | 4/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12522327 | 0.94 | TBK1 (0.59) | TBK1JAK2JAK3IKBKE | |
| SCHEMBL12274845 | 0.91 | TBK1 (0.66) | TBK1JAK2JAK3IKBKEJAK1 | |
| SCHEMBL12274965 | 0.90 | TBK1 (0.62) | TBK1JAK2JAK3IKBKEJAK1 | |
| SCHEMBL1667705 | 0.89 | TBK1 (0.62) | TBK1JAK2JAK3IKBKEJAK1 | |
| SCHEMBL12274829 | 0.88 | TBK1 (0.67) | TBK1JAK2IKBKE | |
| SCHEMBL12274726 | 0.87 | TBK1 (0.62) | TBK1JAK2JAK3 | |
| SCHEMBL12274555 | 0.87 | TBK1 (0.72) | TBK1JAK2JAK3IKBKEJAK1 | |
| SCHEMBL12275606 | 0.86 | TBK1 (0.70) | TBK1JAK2IKBKE | |
| SCHEMBL12522351 | 0.86 | TBK1 (0.66) | TBK1JAK2IKBKE | |
| SCHEMBL12274014 | 0.86 | TBK1 (0.64) | TBK1JAK2JAK3IKBKEJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | TBK1 1/4885JAK2 458/4885JAK3 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.